The founder shareholders of the German biotech company IMD Natural Solutions GmbH (INS) and the listed Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun) in Shanghai, have agreed on Hisun acquiring a minority participation of appr. 21% in INS. A milestone of the agreement is a long-term collaboration between INS and Hisun with respect to the production, marketing and distribution as well as the research and development (R&D) of certain pharmaceutical products. King & Wood Mallesons advised Hisun on the acquisition of this minority stake considering the complex requirements in the area of R&D.

Hisun is a leading Chinese pharmaceutical company principally engaged in the manufacture and distribution of pharmaceuticals. Hisun also involves in the sale of drugs manufactured by other companies and distributes its products in domestic and overseas markets.

IMD Natural Solutions GmbH is a natural product chemistry expert, active in the area of fine and special chemicals derived from natural sources. As such, INS develops, produces and delivers innovative natural additives and active ingredients for the fast moving consumer goods industries. The company's product portfolio in particular comprises natural preservatives and taste modifiers. In addition, INS provides R&D services to customers in the life science industries.

Consultants Hisun

King & Wood Mallesons LLP, Germany:

Dr. Franz Schaefer (Partner Corporate, Munich), Dr. Axel Walz (Partner IP/IT, Munich), Massimo Bellitto-Grillo (Managing Associate IP/IT; all Munich), Johanna Marniok (Managing Associate Corporate, Frankfurt), Weirong Zhang (Associate Corporate, Munich)

King & Wood Mallesons LLP, China:

David Tiang (Partner Corporate, Shanghai)